Innote (688253.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 4...
According to the Zhitong Finance App, Innote (688253.SH) released its 2023 annual report. During the reporting period, the company achieved revenue of 478 million yuan, an increase of 7.03% over the previous year. Achieved net profit of 174 million yuan attributable to shareholders of listed companies, an increase of 15.44% over the previous year. Achieved net profit of 147 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 10.99% over the previous year. Basic earnings per share were $1.28. It is proposed to distribute a cash dividend of 4.00 yuan (tax included) for every 10 shares to all shareholders.
In 2023, benefiting from various factors such as the continuous advancement of the national hierarchical diagnosis and treatment system, the publication of a number of respiratory related clinical practice guidelines and expert consensus, and increased patients' awareness of early diagnosis and treatment, the field of respiratory pathogen detection is in a period of rapid development. During the reporting period, the company stepped up its efforts to develop the market for grade hospitals and primary care. The terminal market coverage rate continued to increase. The non-COVID-19 business achieved revenue of 420 million yuan, an increase of 208.23% over the previous year, driving the company's overall revenue to maintain positive growth.